EXEL announced that the FDA has approved the label expansion of its lead drug Cabometyx (cabozantinib). The regulatory body approved Cabometyx for the treatment of adult and pediatric patients 12 ...

EXEL stock gains on the back of encouraging performance of its lead drug Cabometyx and efforts to improve shareholder value. However, the recent rally might limit further gains for shareholders.

Xilio expects to report updated data from the Phase 2 clinical trial in the middle of 2025, including additional response assessments and follow-up. In addition, Xilio continues to enroll patients in ...

The multi-center, first-in-human, open-label, phase 2/3 SKYBRIDGE ... the anti-PD-L1 therapy Tecentriq (atezolizumab). Dose-limiting toxicities: side effects of a treatment that prevent further ...

Exelixis' future depends on trial outcomes and patent risks. Find out why EXEL stock is a "Sell" despite cabozantinib's ...

The FDA approval is based on the results of the open-label KEYNOTE-224 trial ... designation for its PD-L1 inhibitor Tecentriq (atezolizumab) in combination with VEGF inhibitor Avastin (bevacizumab).

At the same time, one of the latest milestones in Amgen's oncology franchise was the FDA ... (atezolizumab) (OTCQX:RHHBY). Given the data below, I believe it has high potential to expand its label ...

Roche’s closely-watched combination of two checkpoint inhibitors – TIGIT-targeting tiragolumab and PD-L1 drug Tecentriq ... response seen with Tecentriq (atezolizumab) alone.

In December 2024, BioNTech initiated a global randomized Phase 3 clinical trial (NCT06712355) evaluating BNT327 plus chemotherapy compared to atezolizumab plus chemotherapy ... a TROP2-targeted ...

Conversely, the S1605 single-arm Phase II trial of atezolizumab in BCG unresponsive disease was recently closed due to meeting its futility endpoint. Finally, vincinium is not yet widely available but ...

The FDA approved an expanded label for Iluvien, which is now indicated for the treatment of chronic noninfectious uveitis ...